The promising preclinical activity of this class of compounds has stimulated studies aiming at identifying possible mechanisms of resistance. It has been reported that, in cell lines defective in proteins belonging to the nucleotide excision repair (NER) pathway, tallimustine and CC1065 were only slightly less active than in repair-proficient parental cell lines, while major groove alkylating compounds such as melphalan or cis-diammine dichloro platinum (II) (CDDP), were much more active in NERdeficient cell lines (Damia et al, 1996b) . Moreover, cell lines overexpressing N3-adenine glycosylase had the same susceptibility to tallimustine and CC1065 as parental cell lines (Damia et al, 1996a) . Proteins belonging to the mismatch repair (MMR) family play an important role in the resistance to alkylating agents and recognition of certain types of major groove DNA damage (Karran and Bignami, 1994; Branch et al, 1993 Branch et al, , 1995 Fink et al, 1996; Drummond et al, 1996) . Loss of MMR is associated with the development of resistance to monofunctional methylating agents and tolerance to O6-methyl guanine adducts in DNA. Furthermore, cell lines selected for resistance to the bifunctional alkylating agent CDDP were shown to have lost MMR activity (Drummond et al, 1996) and expression of hMLH1 (Brown et al, 1997) . Restoration of MMR activity by re-expression of hMLH1 or hMSH2 by chromosome transfer confers increased sensitivity to these agents (Koi et al., 1994; Aebi et al, 1996 Aebi et al, , 1997 . For different major groove alkylating agents, sensitivity of MMRdeficient cell lines was reported to be lower than that observed in mismatch-proficient cell lines (Koi et al, 1994; Anthoney et al, 1996; Aebi et al, 1997; Fink et al, 1997) . We report here that minor Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents groove alkylating agents are also susceptible to the status of MMR and that loss of MMR activity is associated with a decreased activity of all the tested alkylating minor groove binders. The nonalkylating minor groove binder (MGB) PNU 151807 retained its activity irrespective of the MMR status of the cell lines used.
MATERIALS AND METHODS

Cell lines
The hMLH1-deficient human colorectal adenocarcinoma cell line HCT-116 and the subline into which a wild-type copy hMLH1 on chromosome 3 has been introduced by microcell fusion (HCT116+ch3) (Koi et al, 1994) were obtained from Dr G Marra, Zurich. Both cell lines were grown in medium with 400 µg ml -1 of G418 (Sigma). The human ovarian cancer cell line A2780 and two CDDP-resistant sublines that have lost hMLH1 expression (Brown et al, 1997) were grown in RPMI-1640 medium (GIBCO) supplemented with 10% fetal calf serum (FCS). A2780/CP70+ch3 clone was obtained from CDDP-resistant, hMLH1-deficient cell line A2780/CP70 by introducing chromosome 3 by microcellmediated chromosome transfer and was maintained in the same medium as A2780/CP70 cells in the presence of 200 U ml -1 of Hygromycin B (Boehringer, Italy).
Drugs and inhibition of colony formation
For clonogenic assay, cells were plated at 250 cells cm -2 , treated with different concentrations of compounds for 1 h and incubated for 10-14 days in drug-free medium; the number of colonies formed (roughly 50 cells) were counted after staining with Giemsa.
Student's t-test analysis was performed to evaluate differences between parental and chromosome transfected cell lines. IC 50 values calculated from three independent experiments, each consisting of at least three replicates, were used.
Tallimustine, CC1065, PNU 151807 and carzelesin (see structure in Figure 1 ) were obtained from Pharmacia & Upjohn (Nerviano, Italy), dissolved as stock solutions in dimethyl sulphoxide (DMSO) and diluted in medium just prior to use. CDDP was obtained from Bristol Myers Squibb and dissolved in medium just prior to use. N-methyl-N-nitro-N-nitrosoguanosine (MNNG) was purchased from Sigma, dissolved in DMSO and subsequently diluted in medium. 
RESULTS
The cytotoxicity induced by tallimustine, carzelesin, CC1065 and PNU 151807 was evaluated by clonogenic assay in HCT-116 and HCT-116+ch3 cell lines (Figure 2 ), in comparison with CDDP and MNNG, agents known to exert differential activity in these two cell lines. As shown in Figure 2 , the introduction of chromosome 3 in HCT-116 cells results in an increased sensitivity of the cells to the treatment with the three alkylating minor groove binders, but not to the non-covalent MGB PNU 151807, which was equally active in both cell lines. The relative IC 50 values calculated from the curves shown in Figure 2 are reported in Table 1 where it can be seen that the three alkylating MGB are approximately 2-3 times less active in mismatch-deficient HCT-116 cells than in mismatchproficient HCT-116+ch3 cells. The difference in activity observed after MNNG treatment was much greater.
The same experiments were performed in another wellcharacterized system, the human ovarian cancer cell line A2780 (mismatch-proficient) and two sublines, A2780/CP70 and A2780/MCP-1 (obtained as CDDP-resistant clones from A2780 cells), which have been shown to lack expression of hMLH1 protein (Brown et al, 1997) . In this system, the three alkylating MGB showed, as in the colocarcinoma cell lines, less activity in the two mismatch-deficient cell lines (Figure 3) and the degree of resistance, calculated from the IC 50 values, was similar to that found for CDDP (data not shown). The non-alkylating MGB PNU 151807 was also more active in parental A2780 cells than in the two CDDP-resistant clones. As shown in Figure 4 and Table 2 , re-expression of hMLH1 in these cells by chromosome transfer partially restores sensitivity to CDDP and the three alkylating MGB, but not to the non-alkylating MGB PNU 151807. A2780/CP70 have previously been shown to have a number of alterations that could affect drug sensitivity. The data presented support a role for MMR in cytotoxicity of the alkylating MGB, but the non-alkylating MGB PNU 151807 retained its activity independently of the mismatch repair status.
DISCUSSION
The MMR system plays an important role in the control of genomic integrity in cells (Karran and Bignami, 1994; Fishel and Kolodner, 1995; Karran and Hampson, 1996) . It has been reported in different experimental systems that defects in MMR proteins confer tolerance to methylating agents and also to some other cytotoxic agents, including CDDP . Furthermore, selection of CDDP-resistant cell lines can result in loss of the expression of these proteins (Drummond et al, 1996; Brown et al, 1997) . Recently, it has been reported that biopsies of residual disease from human ovarian tumours after chemotherapy showed a higher incidence of loss of hMLH1 expression compared to untreated tumours (Brown et al, 1997) .
If loss of MMR is indeed relevant for clinical resistance to chemotherapy, this has an important implication for the selection and use of new therapeutic compounds. Thus, compounds not requiring MMR to mediate toxicity will have a different mechanism of action and will have activity in MMR-deficient tumours.
In the present study we show that minor groove alkylating agents, a new emerging class of anticancer agents, also utilize MMR to mediate their tumour cell killing. This is a new finding which increases the number of DNA lesions potentially recognized by the MMR proteins. It should be noted that, in contrast to CDDP which induces a relatively high number of drug adducts in the major groove of DNA, all the three alkylating MGB tested produced only a limited number of DNA lesions (Hurley et al, 1984; Broggini et al, 1991 Broggini et al, , 1995 . This is particularly true for tallimustine which is able to alkylate the N3 of adenine only when present in the hexamer sequence 5′-TTTTGA (Broggini et al, 1995) . Despite the different number of DNA lesions induced, the three alkylating MGB showed roughly the same ratio of activity between mismatch-proficient and mismatch-deficient cells observed for CDDP. While it does appear that the MMR-associated resistance does not apply to all the major groove alkylating agents (as reported for example for melphalan, which was able to induce the same cytotoxicity in HCT-116 and HCT-116+ch3 cells) for the minor groove binders, all three compounds tested showed MMR deficiency-associated resistance in both experimental systems used. The non-alkylating MGB PNU 151807 appears to be insensitive to the presence of MMR proteins. This is, in our opinion, an interesting finding, due to the high preclinical anti-tumour activity and the relatively low haematological toxicity shown for this compound (D'Alessio et al, 1994; Ghielmini et al, 1997) , and makes it a good future candidate for the treatment of tumours responsive to MGB but presenting alterations in the MMR pathway. As a collateral result we observed that CDDP-resistant cell lines, CP70 and MCP1, are crossresistant to PNU 151807. However, this resistance is not associated with MMR deficiency, since there is no reversal of resistance in CP70+ch3 cells to the PNU 151807, despite observed reversal resistance for the three alkylating MGB. It must be noted that PNU 151807 is, like tallimustine, a derivative of the non-cytotoxic compound, distamycin A (D 'Alessio et al, 1994) . Both PNU 151807 and tallimustine showed the same non-covalent DNA interaction, as suggested by footprinting experiments reporting the protection of the same AT-rich region in different DNA fragments (Marchini et al, submitted for publication). The similar activity of PNU 151807 in MMR-proficient and MMR-deficient cells is thus likely to be solely due to the lack of alkylation produced by this compound.
In conclusion, we have shown that some minor groove alkylating agents are processed by the MMR system as has previously been observed for major groove DNA binders. The availability of an active, MMR deficiency-insensitive, nonalkylating anti-tumour agent still binding in the minor groove, could be an important alternative to the clinical use of MGB in MMR-deficient tumours.
